Literature DB >> 30891126

PROTAC Molecules for the Treatment of Autoimmune Disorders.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 30891126      PMCID： PMC6421524          DOI： 10.1021/acsmedchemlett.9b00042

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

1.  Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.

Authors:  Ryan P Wurz; Victor J Cee
Journal:  J Med Chem       Date:  2018-12-21       Impact factor: 7.446

Review 2.  Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.

Authors:  Philipp Ottis; Craig M Crews
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

Review 3.  Targeted protein degradation by PROTACs.

Authors:  Taavi K Neklesa; James D Winkler; Craig M Crews
Journal:  Pharmacol Ther       Date:  2017-02-14       Impact factor: 12.310

Review 4.  Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Authors:  Ian Churcher
Journal:  J Med Chem       Date:  2017-12-19       Impact factor: 7.446

Review 5.  The PROTAC technology in drug development.

Authors:  Yutian Zou; Danhui Ma; Yinyin Wang
Journal:  Cell Biochem Funct       Date:  2019-01-02       Impact factor: 3.685
  5 in total
  1 in total

Review 1.  Discovery of E3 Ligase Ligands for Target Protein Degradation.

Authors:  Jaeseok Lee; Youngjun Lee; Young Mee Jung; Ju Hyun Park; Hyuk Sang Yoo; Jongmin Park
Journal:  Molecules       Date:  2022-10-02       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.